95 related articles for article (PubMed ID: 16261166)
81. Loss of Brca2 and p53 synergistically promotes genomic instability and deregulation of T-cell apoptosis.
Cheung AM; Hande MP; Jalali F; Tsao MS; Skinnider B; Hirao A; McPherson JP; Karaskova J; Suzuki A; Wakeham A; You-Ten A; Elia A; Squire J; Bristow R; Hakem R; Mak TW
Cancer Res; 2002 Nov; 62(21):6194-204. PubMed ID: 12414647
[TBL] [Abstract][Full Text] [Related]
82. Redundant and differential regulation of multiple licensing factors ensures prevention of re-replication in normal human cells.
Sugimoto N; Yoshida K; Tatsumi Y; Yugawa T; Narisawa-Saito M; Waga S; Kiyono T; Fujita M
J Cell Sci; 2009 Apr; 122(Pt 8):1184-91. PubMed ID: 19339550
[TBL] [Abstract][Full Text] [Related]
83. Functional interplay of p53 and Mus81 in DNA damage responses and cancer.
Pamidi A; Cardoso R; Hakem A; Matysiak-Zablocki E; Poonepalli A; Tamblyn L; Perez-Ordonez B; Hande MP; Sanchez O; Hakem R
Cancer Res; 2007 Sep; 67(18):8527-35. PubMed ID: 17875692
[TBL] [Abstract][Full Text] [Related]
84. Geminin is essential for the development of preimplantation mouse embryos.
Hara K; Nakayama KI; Nakayama K
Genes Cells; 2006 Nov; 11(11):1281-93. PubMed ID: 17054725
[TBL] [Abstract][Full Text] [Related]
85. The ataxia telangiectasia-mutated target site Ser18 is required for p53-mediated tumor suppression.
Armata HL; Garlick DS; Sluss HK
Cancer Res; 2007 Dec; 67(24):11696-703. PubMed ID: 18089799
[TBL] [Abstract][Full Text] [Related]
86. Cdt1 transgenic mice develop lymphoblastic lymphoma in the absence of p53.
Seo J; Chung YS; Sharma GG; Moon E; Burack WR; Pandita TK; Choi K
Oncogene; 2005 Dec; 24(55):8176-86. PubMed ID: 16261166
[TBL] [Abstract][Full Text] [Related]
87. Geminin-Cdt1 balance is critical for genetic stability.
Saxena S; Dutta A
Mutat Res; 2005 Jan; 569(1-2):111-21. PubMed ID: 15603756
[TBL] [Abstract][Full Text] [Related]
88.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
89.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
90.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
91.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
92.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
93.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
94.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
95.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [New Search]
